Navigation Links
NeoPharm Provides Update on LE-SN38 Program

WAUKEGAN, Ill.--(BUSINESS WIRE)--Mar 30, 2007 - NEOPHARM, Inc. (Nasdaq: NEOL) today reported findings from a Phase 2 clinical trial in second-line metastatic colorectal cancer patients with its drug product candidate LE-SN38, the active metabolite of irinotecan (Camptosar(R)). While the interim analysis of data following the completion of treatment of the first 21 patients demonstrated disease stabilization, the study did not achieve the primary tumor response endpoint. No new patient accrual will be made into this study conducted by the Cancer and Leukemia Group B (CALGB), a national clinical research group sponsored by the National Cancer Institute (NCI). Patients currently receiving therapy will continue treatment per protocol until a study endpoint is reached. NeoPharm will be reassessing project next steps including additional data analyses and the possibility of other studies.

About NEOPHARM, Inc.

NEOPHARM, Inc., based in Waukegan, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. Additional information, including ongoing clinical trials, can be obtained by visiting NEOPHARM's Web site at www.neopharm.com.

Forward Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company's drug development program, the initiation, progress and outcomes of clin
'"/>




Page: 1 2

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. XTL Provides Update on Phase I Clinical Trial of XTL-2125
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
5. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
6. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
7. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
8. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
9. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
10. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
11. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NeoPharm Provides Update Program
(Date:8/31/2015)... 2015 Regen BioPharma, Inc. (OTCBB: RGBP) ... novel means of delivering its patented (US Patent ... tumors utilizing a clinically approved formulation as delivery ... with gene silencing therapeutics in which the gene ... whole body.  By utilizing a local delivery system, ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , Aug. ... ; EURONEXT: SAN) and the life sciences team at ... care and outcomes for people with type 1 and ... treatments and devices with Google,s expertise in analytics, miniaturized ... explore how to improve diabetes care by developing new ...
(Date:8/31/2015)...  Qualcomm Incorporated (NASDAQ: QCOM ) today ... is collaborating with Davita Healthcare Partners and ... by Qualcomm Life,s 2net™ Device Connectivity Platform and ... informed interventions and better management of at-risk populations. ... Connect 2015 ecosystem conference taking place ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... 7, 2011  Tethys Bioscience has entered into an agreement ... employers measurably flatten the trajectory of their healthcare trends ... their employee populations. The agreement allows ACAP Health to ... as a component of its disease intervention programs. The ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... of the granting of a European patent with broad ... diketopiperazine which is the active ingredient of Ampion™.  The ...
Cached Medicine Technology:Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 2Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 3Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™ 2
(Date:9/1/2015)... ... 01, 2015 , ... Dr. Trace Curry successfully placed one of the first ... last month the FDA has approved two intra-gastric balloons, the ORBERA ™ Managed ... first incisionless, reversible, weight loss procedures available to Americans. , Dr. Curry, ...
(Date:9/1/2015)... Pasadena, California (PRWEB) , ... September 01, 2015 ... ... Anna Arrowsmith interviewed dating men and pick-up artists about their experiences of female ... alongside men’s bodily concerns, including penis issues, as well as their relationships with ...
(Date:9/1/2015)... ... ... A new episode of “Voices In America”, hosted by famous actor and ... arthritis. There are over 100 different types of arthritis. One of the most popular ... effort to shed light on this important topic. , Anyone who is nearing their ...
(Date:9/1/2015)... ... 2015 , ... The premier online medical education company for ... in podiatric, surgical and wound care conferences . The Residency Education Summits ... at the podium and across the table during hands-on surgical and advanced wound ...
(Date:8/31/2015)... ... September 01, 2015 , ... Spinal fusion surgery – ... required a long, arduous recovery. However, today’s minimally invasive fusions achieve similar results ... and minimal muscle damage. These advantages of minimally invasive surgery redeem the procedure’s ...
Breaking Medicine News(10 mins):Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4
... A study finds that sleep deprivation can adversely affect ... the expectation of gains and making light of ... understand the neural underpinnings of risky decision making under ... Duke University studied healthy volunteers as they underwent functional ...
... older women - those 80 or older - have the greatest ... today. ,Worryingly, the research also found that 56 per ... cancer risk. ,The strongest risk factor for breast cancer ... her risk. About one in 70 women will develop breast cancer ...
... risk of cancer; a Danish study conducted amongst 28,000 ... ,Danish medical records were analyzed to monitor ... among the utility workers for 23years. This was done ... and its effects. ,The researchers did not ...
... definite link between pregnancy, migraine and stroke, US researchers ... one. ,In fact, Cheryl Bushnell, assistant professor ... Disease in Durham, explained that pregnant women who suffered ... than pregnant women who did not suffer migraine. ...
... talked about testosterone cream for enhancing sexual desire in female ... conducted by Mayo clinic has shown. ... As an extension to a previous study which pointed a ... with sufficient estrogen levels, this new study was conducted on ...
... one out of depression. But its potential to drive ... ,Now the U.S. Food and Drug Administration (FDA) ... the existing black box warning on their products' labeling ... and behavior, in young adults ages 18 to 24 ...
Cached Medicine News:Health News:Sleep Deprivation can Affect Competent Decision-making 2Health News:Women Unaware of When Breast Cancer Risk is Greatest 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 3
Open blade design with aspiration capabilities for removing fluids from the operative site. 19 gauge wire....
Designed to provide open approaches of the keratome to the cornea for either the left or right eye. Lightweight wire design adds to the comfort of the instrument when in place....
Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: